Alex Holmes Louis Irving Associate Professor of Physiology, The University of Melbourne
But some people, estimated to be roughly 10-30% of people who get COVID, suffer persistent symptoms colloquially known as “long COVID”.
Why do some people recover quickly, while others’ symptoms continue for months? This question has proved to be one of the most challenging to emerge from the COVID-19 pandemic.
While there’s no definitive answer yet, there are a few leading theories put forward by researchers around the world.
So what have we learned about long COVID, and what is the latest evidence telling us so far?
Happy birthday, Gus Nossal
th birthday today.
Gus Nossal in 1988. Credit: Impressions / Getty Images
Sir Gustav Nossal (born 4 June 1931) is an internationally renowned immunologist. Nossal directed the Walter and Eliza Hall Institute for 31 years, from 1965 to 1996. He is also an Emeritus Professor at the University of Melbourne, and he served as President of the Australian Academy of Science from 1994 to 1998.
His research focussed on how the immune system makes antibodies to ward off infectious diseases. He also did significant work on immunological tolerance, showing how the immune system can distinguish between foreign agents and the body – noting how it can break down in autoimmune diseases.
Advertisement
Richard Edwards hates panic buyers.
But after traipsing to four supermarkets in February in search of toilet paper – and without the convenience of a car – he became one of them.
Richard Edwards says he was caught short once and now always keeps the cupboard well stocked.
Credit:Simon Schluter
The 48-year-old now buys the household staple in bulk packs of 32 and always ensures his home in Melbourne’s south-west is well stocked.
“I was caught short and swore to myself that I was never going through that again,” said the Laverton resident, who is a full-time carer for his 70-year-old mother.
01.06.2021: Australia's top biomedical researchers are invited to apply for one of two CSL Centenary Fellowships worth $1.25 million over five years in.
Posted on 539
ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has entered into an exclusive global patent license agreement with Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI) providing rights to CISH KO in the field of NK cells for the treatment of cancer.
“Deletion of CISH in NK cells leads to an improved metabolic profile, greatly enhances their proliferation, cytotoxicity, and persistence.
In-vivo models of cancer have shown that CISH KO NK cells are much more efficient in eliminating cancer cells, making such cells a very attractive prospect for future clinical development,” said Prof Michael O’Dwyer, CSO of ONK Therapeutics.